TYRO3, AXL and MERTK (TAM) rely on a unique mode of receptor tyrosine kinase (RTK) regulation — which involves a protein ligand and a lipid (phosphatidylserine) complex that binds to the extracellular domain — to trigger dimerization and kinase activation.
MERTK initiates efferocytosis in macrophages and epithelial cells, which has a crucial role in the efficient clearance of apoptotic material.
MERTK and AXL function in innate immune cells to suppress inflammatory responses.
Genetic deletion of Mertk in mice leads to autoimmunity, and additional deletion of Axl and Tyro3 increases the autoimmune, inflammatory response.
TAM RTKs carry out their physiological innate immune functions within tumours and thereby promote an immunosuppressive tumour microenvironment.
TAM RTKs and their ligands are overexpressed in neoplastic cells. Autocrine and paracrine stimulation of aberrantly expressed TAM RTKs provide intrinsic survival signals and promote resistance to molecularly targeted and cytotoxic therapies.
AXL has normal roles in vasculogenesis and in the migration of cells during development; AXL expression correlates with metastasis, epithelial-to-mesenchymal transition and motility in tumours.
TAM RTKs represent a dual target in neoplastic disease given their intrinsic roles in tumour cell survival and chemoresistance, and their immunosuppressive roles in the tumour microenvironment.
The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies. Rather than functioning as oncogenic drivers, their induction in tumour cells predominately promotes survival, chemoresistance and motility. The unique mode of maximal activation of this RTK family requires an extracellular lipid–protein complex. For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages. This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization. In tumours, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumour cell and favour an anti-inflammatory, immunosuppressive microenvironment. Thus, TAM kinase inhibition could stimulate antitumour immunity, reduce tumour cell survival, enhance chemosensitivity and diminish metastatic potential.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Graham, D. K., Dawson, T. L., Mullaney, D. L., Snodgrass, H. R. & Earp, H. S. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 5, 647–657 (1994). This paper describes the identification and sequencing of MERTK , as well as its expression in a range of cancer cell lines, including ectopic expression in lymphoblastic leukaemia.
O'Bryan, J. P. et al. AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11, 5016–5031 (1991). This paper describes the identification and cloning of AXL from two independent samples from patients with CML, and transforming activity was shown in NIH3T3 cells.
Lai, C., Gore, M. & Lemke, G. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene 9, 2567–2578 (1994). This paper describes the identification, sequencing and transforming activity of TYRO3 in fibroblasts.
Linger, R. M., Keating, A. K., Earp, H. S. & Graham, D. K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35–83 (2008).
Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nature Rev. Immunol. 8, 327–336 (2008).
Ling, L. & Kung, H. J. Mitogenic signals and transforming potential of NYK, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol. Cell. Biol. 15, 6582–6592 (1995).
Lapraz, F. et al. RTK and TGF-β signaling pathways genes in the sea urchin genome. Dev. Biol. 300, 132–152 (2006).
Lai, C. & Lemke, G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6, 691–704 (1991). This paper is the first to identify novel kinase domain sequences, including those of the TAMs, in RNA from the developing vertebrate nervous system using PCR.
Jia, R., Mayer, B. J., Hanafusa, T. & Hanafusa, H. A novel oncogene, v-RYK, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J. Virol. 66, 5975–5987 (1992).
Keating, A. K. et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the MER (MERTK) receptor tyrosine kinase. Oncogene 25, 6092–6100 (2006). This paper shows that Mertk -transgenic mice with ectopic MERTK expression in haematopoietic cells develop lymphoblastic leukaemia/lymphoma.
Guttridge, K. L. et al. MER receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J. Biol. Chem. 277, 24057–24066 (2002).
Goruppi, S., Ruaro, E., Varnum, B. & Schneider, C. GAS6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of RAS. Oncogene 18, 4224–4236 (1999).
Melaragno, M. G. et al. GAS6 inhibits apoptosis in vascular smooth muscle: role of AXL kinase and AKT. J. Mol. Cell Cardiol. 37, 881–887 (2004).
Bellosta, P., Zhang, Q., Goff, S. P. & Basilico, C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15, 2387–2397 (1997). In this study, AXL stimulation activated signalling through oncogenic pathways and promoted cell survival in response to apoptotic stimuli.
Varnum, B. C. et al. AXL receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373, 623–626 (1995).
Stitt, T. N. et al. The anticoagulation factor protein S and its relative, GAS6, are ligands for the TYRO3/AXL family of receptor tyrosine kinases. Cell 80, 661–670 (1995).
Nagata, K. et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for AXL, SKY, and MER receptor tyrosine kinases. J. Biol. Chem. 271, 30022–30027 (1996). References 15–17 identify GAS6 and PROS1 as TAM receptor ligands and suggest a role for TAM RTKs in conditions of cellular stress.
Sasaki, T. et al. Structural basis for GAS6–AXL signalling. EMBO J. 25, 80–87 (2006).
Tsou, W. I. et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J. Biol. Chem. 289, 25750–25763 (2014).
Lew, E. D. et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife 3, e03385 (2014). References 19 and 20 are recent detailed studies showing differential binding, receptor activation and functions mediated by TAM RTK ligands.
Zagorska, A., Traves, P. G., Lew, E. D., Dransfield, I. & Lemke, G. Diversification of TAM receptor tyrosine kinase function. Nature Immunol. 15, 920–928 (2014).
Caberoy, N. B., Zhou, Y. & Li, W. Tubby and tubby-like protein 1 are new MERTK ligands for phagocytosis. EMBO J. 29, 3898–3910 (2010).
Caberoy, N. B., Alvarado, G. & Li, W. Tubby regulates microglial phagocytosis through MERTK. J. Neuroimmunol. 252, 40–48 (2012).
Caberoy, N. B., Alvarado, G., Bigcas, J. L. & Li, W. Galectin-3 is a new MERTK-specific eat-me signal. J. Cell. Physiol. 227, 401–407 (2012).
Scott, R. S. et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207–211 (2001).
Chen, C. et al. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb. Vasc. Biol. 24, 1118–1123 (2004).
Angelillo-Scherrer, A. et al. Role of GAS6 in erythropoiesis and anemia in mice. J. Clin. Invest. 118, 583–596 (2008).
Eken, C. et al. Ectosomes released by polymorphonuclear neutrophils induce a MERTK-dependent anti-inflammatory pathway in macrophages. J. Biol. Chem. 285, 39914–39921 (2010).
Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531–535 (2008).
Bhattacharyya, S. et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14, 136–147 (2013).
Cook, R. S. et al. MERTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J. Clin. Invest. 123, 3231–3242 (2013). In this study, Mertk−/− mice showed a pro-inflammatory state in the microenvironment of orthotopically implanted tumours, resulting in inhibition of tumour growth and metastasis.
Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508–512 (2014). This paper identifies TAM RTKs as key proteins targeted by CBLB in NK cells and implicates TAM RTK signalling in the suppression of NK cell activity, allowing enhanced metastasis.
Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124–1136 (2007).
Seitz, H. M., Camenisch, T. D., Lemke, G., Earp, H. S. & Matsushima, G. K. Macrophages and dendritic cells use different AXL/MERTK/TYRO3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635–5642 (2007).
Filardy, A. A. et al. Proinflammatory clearance of apoptotic neutrophils induces an IL-12lowIL-10high regulatory phenotype in macrophages. J. Immunol. 185, 2044–2050 (2010). This paper shows that MERTK-mediated efferocytosis polarizes macrophages towards an M2-phenotype.
D'Cruz, P. M. et al. Mutation of the receptor tyrosine kinase gene MERTK in the retinal dystrophic RCS rat. Hum. Mol. Genet. 9, 645–651 (2000). This paper maps genetic retinal dystrophy in a rat model to a deletion in the Mertk gene, resulting in failure to engulf apoptotic material shed nightly in the retina.
Gal, A. et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nature Genet. 26, 270–271 (2000).
Duncan, J. L. et al. An RCS-like retinal dystrophy phenotype in Mer-knockout mice. Invest. Ophthalmol. Vis. Sci. 44, 826–838 (2003).
Conlon, T. J. et al. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum. Gene Ther. Clin. Dev. 24, 23–28 (2013).
Sandahl, M., Hunter, D. M., Strunk, K. E., Earp, H. S. & Cook, R. S. Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation. BMC Dev. Biol. 10, 122 (2010).
Shao, W. H. et al. A protective role of MER receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin. Immunol. 136, 236–244 (2010).
Sun, B. et al. Sertoli cell-initiated testicular innate immune response through Toll-like receptor-3 activation is negatively regulated by TYRO3, AXL, and MER receptors. Endocrinology 151, 2886–2897 (2010).
Ji, R. et al. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J. Immunol. 191, 6165–6177 (2013).
Chung, W. S. et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394–400 (2013).
Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MERTK induction. J. Immunol. 189, 3508–3520 (2012).
Shao, W. H., Zhen, Y., Eisenberg, R. A. & Cohen, P. L. The MER receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses GAS6 as its ligand for uptake of apoptotic cells. Clin. Immunol. 133, 138–144 (2009).
Lee-Sherick, A. B. et al. Aberrant MER receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 32, 5359–5368 (2013).
Mahajan, N. P. & Earp, H. S. An SH2 domain-dependent, phosphotyrosine-independent interaction between VAV1 and the MER receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J. Biol. Chem. 278, 42596–42603 (2003).
Lee, Y. J. et al. Preventing cleavage of MER promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. Toxicol. Appl. Pharmacol. 263, 61–72 (2012).
Wan, E. et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ. Res. 113, 1004–1012 (2013).
Camenisch, T. D., Koller, B. H., Earp, H. S. & Matsushima, G. K. A novel receptor tyrosine kinase, MER, inhibits TNFα production and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162, 3498–3503 (1999).
Tibrewal, N. et al. Autophosphorylation docking site Tyr-867 in MER receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J. Biol. Chem. 283, 3618–3627 (2008).
Sen, P. et al. Apoptotic cells induce MER tyrosine kinase-dependent blockade of NF-κB activation in dendritic cells. Blood 109, 653–660 (2007).
Wallet, M. A. et al. MERTK is required for apoptotic cell-induced T cell tolerance. J. Exp. Med. 205, 219–232 (2008).
Alciato, F., Sainaghi, P. P., Sola, D., Castello, L. & Avanzi, G. C. TNFα, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J. Leukoc. Biol. 87, 869–875 (2010).
Park, H. J., Baen, J. Y., Lee, Y. J., Choi, Y. H. & Kang, J. L. The TAM-family receptor MER mediates production of HGF through the RHOA-dependent pathway in response to apoptotic cells. Mol. Biol. Cell 23, 3254–3265 (2012).
Carrera Silva, E. A. et al. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 39, 160–170 (2013). This paper shows that activated T cells induce PROS1 and externalize PtdSer, thereby stimulating TAM RTKs on APCs and reducing the immune response.
Cohen, P. L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-MER membrane tyrosine kinase. J. Exp. Med. 196, 135–140 (2002).
Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the TYRO3 family. Science 293, 306–311 (2001).
Rothlin, C. V., Leighton, J. A. & Ghosh, S. TYRO3, AXL, and MERTK receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm. Bowel Dis. 20, 1472–1480 (2014).
Zahuczky, G., Kristof, E., Majai, G. & Fesus, L. Differentiation and glucocorticoid regulated apopto-phagocytic gene expression patterns in human macrophages. Role of MERTK in enhanced phagocytosis. PLoS ONE 6, e21349 (2011).
A.- Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245–258 (2009). This paper shows that apoptotic cell ingestion produces lipid ligands for LXR through intracellular metabolism and that transcription is enhanced when LXR binds to the MERTK promoter.
Kaller, M. et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell Proteomics 10, M111 010462 (2011).
Mudduluru, G. et al. Regulation of AXL receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30, 2888–2899 (2011).
Mackiewicz, M. et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res. Treat. 130, 663–679 (2011).
Giles, K. M. et al. AXL mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12, 2541–2558 (2013).
Png, K. J., Halberg, N., Yoshida, M. & Tavazoie, S. F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481, 190–194 (2012).
Wang, C. P. et al. Identification of a gene encoding a typical γ-carboxyglutamic acid domain in the tunicate Halocynthia roretzi. J. Thromb. Haemost. 1, 118–123 (2003).
Kulman, J. D. et al. Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade. Proc. Natl Acad. Sci. USA 103, 15794–15799 (2006).
Chen, J., Carey, K. & Godowski, P. J. Identification of GAS6 as a ligand for MER, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 14, 2033–2039 (1997).
Burstyn-Cohen, T. et al. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron 76, 1123–1132 (2012).
Angelillo-Scherrer, A. et al. Deficiency or inhibition of GAS6 causes platelet dysfunction and protects mice against thrombosis. Nature Med. 7, 215–221 (2001).
Angelillo-Scherrer, A. et al. Role of GAS6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest. 115, 237–246 (2005).
Linger, R. M. et al. MER receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood 122, 1599–1609 (2013). This paper shows that shRNA-mediated knockdown of MERTK in B-ALL cells abrogates MERTK-mediated survival signalling, decreases colony-forming potential, increases chemosensitivity and prolongs xenograft survival.
Brandao, L. N. et al. Inhibition of MERTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J. 3, e101 (2013).
Waizenegger, J. S. et al. Role of growth arrest-specific gene 6–MER axis in multiple myeloma. Leukemia http://dx.doi.org/10.1038/leu.2014.236 (2014).
Neubauer, A. et al. Expression of AXL, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84, 1931–1941 (1994).
Rochlitz, C. et al. AXL expression is associated with adverse prognosis and with expression of BCL-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13, 1352–1358 (1999).
Park, I. K. et al. Inhibition of the receptor tyrosine kinase AXL impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for AXL as a potential therapeutic target. Blood 121, 2064–2073 (2013).
Ben-Batalla, I. et al. AXL, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122, 2443–2452 (2013).
Dirks, W. et al. Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk. Res. 23, 643–651 (1999).
Ghosh, A. K. et al. The novel receptor tyrosine kinase AXL is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 117, 1928–1937 (2011).
Crosier, P. S., Hall, L. R., Vitas, M. R., Lewis, P. M. & Crosier, K. E. Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk. Lymphoma 18, 443–449 (1995).
De Vos, J. et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98, 771–780 (2001).
Nelson, E. R. et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342, 1094–1098 (2013).
Li, Y. et al. The c-MER gene is induced by Epstein–Barr virus immediate-early protein BRLF1. J. Virol. 78, 11778–11785 (2004).
Rankin, E. B. et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc. Natl Acad. Sci. USA 111, 13373–13378 (2014).
Hong, C. C. et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268, 314–324 (2008).
Mudduluru, G. & Allgayer, H. The human receptor tyrosine kinase Axl gene — promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci. Rep. 28, 161–176 (2008).
Liu, R. et al. Induction, regulation, and biologic function of AXL receptor tyrosine kinase in Kaposi sarcoma. Blood 116, 297–305 (2010).
Kubo, T. et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 30, 1857–1864 (2009).
Margareto, J. et al. DNA copy number variation and gene expression analyses reveal the implication of specific oncogenes and genes in GBM. Cancer Invest. 27, 541–548 (2009).
Tworkoski, K. A. et al. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell. Melanoma Res. 26, 527–541 (2013).
Seo, J. S. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109–2119 (2012).
Nguyen, K. Q. et al. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. J. Biol. Chem. 289, 25737–25749 (2014).
Linger, R. M. et al. MER or AXL receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 32, 3420–3431 (2013).
Shiozawa, Y. et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116–127 (2010).
Shiozawa, Y., Pedersen, E. A. & Taichman, R. S. GAS6/MER axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp. Hematol. 38, 132–140 (2010).
Georgescu, M. M., Kirsch, K. H., Shishido, T., Zong, C. & Hanafusa, H. Biological effects of c-MER receptor tyrosine kinase in hematopoietic cells depend on the GRB2 binding site. Mol. Cell. Biol. 19, 1171–1181 (1999). In this study, a chimeric receptor containing the MERTK kinase domain is generated and is used to show MERTK-dependent signalling through the PI3K, ERK and NF-κB pathways.
Darby, C., Giannola, D. M., Couzens, M. S. & Emerson, S. G. ETK2 receptor tyrosine kinase promotes survival of factor-dependent FDC-P1 progenitor cells. Exp. Hematol. 28, 716–725 (2000).
Fan, L. et al. Expression of MER on Jurkat cells and its anti-apoptosis effect. Ai Zheng 26, 698–702 (2007) (in Chinese).
Rogers, A. E. et al. MER receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 31, 4171–4181 (2012).
Schlegel, J. et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J. Clin. Invest. 123, 2257–2267 (2013). This paper shows MERTK overexpression in melanoma, independent of RAS or BRAF mutation status, and that this correlates with progression to metastasis. It also shows that MERTK inhibition decreases colony formation, invasion and xenograft growth in melanoma models.
Brown, J. E., Krodel, M., Pazos, M., Lai, C. & Prieto, A. L. Cross-phosphorylation, signaling and proliferative functions of the TYRO3 and AXL receptors in Rat2 cells. PLoS ONE 7, e36800 (2012).
Migdall-Wilson, J. et al. Prolonged exposure to a MER ligand in leukemia: GAS6 favors expression of a partial MER glycoform and reveals a novel role for MER in the nucleus. PLoS ONE 7, e31635 (2012).
Lee, W. P., Wen, Y., Varnum, B. & Hung, M. C. AKT is required for AXL–GAS6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21, 329–336 (2002).
Graham, D. K. et al. Ectopic expression of the proto-oncogene MER in pediatric T-cell acute lymphoblastic leukemia. Clin. Cancer Res. 12, 2662–2669 (2006).
Li, Y. et al. AXL as a potential therapeutic target in cancer: role of AXL in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442–3455 (2009).
Hector, A. et al. The AXL receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol. Ther. 10, 1009–1018 (2010).
Holland, S. J. et al. R428, a selective small molecule inhibitor of AXL kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544–1554 (2010). This paper shows that treatment with R428, a selective and orally bioavailable small-molecule AXL kinase inhibitor, reduces metastasis of breast cancer xenografts in mice.
Ye, X. et al. An anti-AXL monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254–5264 (2010).
Sensi, M. et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional AXL receptor kinase. J. Invest. Dermatol. 131, 2448–2457 (2011).
Song, X. et al. Overexpression of receptor tyrosine kinase AXL promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117, 734–743 (2011).
Christoph, S. et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol. Cancer Ther. 12, 2367–2377 (2013).
Leconet, W. et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene http://dx.doi.org/10.1038/onc.2013.487 (2013).
Keating, A. K. et al. Inhibition of MER and AXL receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol. Cancer Ther. 9, 1298–1307 (2010).
Dunne, P. D. et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res. 20, 164–175 (2014).
Lay, J. D. et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 67, 3878–3887 (2007).
Tai, K. Y., Shieh, Y. S., Lee, C. S., Shiah, S. G. & Wu, C. W. AXL promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1. Oncogene 27, 4044–4055 (2008).
Paccez, J. D. et al. The receptor tyrosine kinase AXL is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32, 689–698 (2013).
Asiedu, M. K. et al. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33, 1316–1324 (2014).
Lee, C. H. et al. Tumor-associated macrophages promote oral cancer progression through activation of the AXL signaling pathway. Ann. Surg. Oncol. 21, 1031–1037 (2014).
Papadakis, E. S. et al. AXL promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic BCL-2 family members. J. Invest. Dermatol. 131, 509–517 (2011).
Nur, E. K. A. et al. Requirement of activated CDC42-associated kinase for survival of v-RAS-transformed mammalian cells. Mol. Cancer Res. 3, 297–305 (2005).
Melaragno, M. G., Fridell, Y. W. & Berk, B. C. The GAS6/AXL system: a novel regulator of vascular cell function. Trends Cardiovasc. Med. 9, 250–253 (1999).
Ruan, G. X. & Kazlauskas, A. AXL is essential for VEGF-A-dependent activation of PI3K/AKT. EMBO J. 31, 1692–1703 (2012).
Fraineau, S. et al. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a MER- and SHP2-dependent manner. Blood 120, 5073–5083 (2012).
Suleiman, L., Negrier, C. & Boukerche, H. Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit. Rev. Oncol. Hematol. 88, 637–654 (2013).
Burstyn-Cohen, T., Heeb, M. J. & Lemke, G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J. Clin. Invest. 119, 2942–2953 (2009).
Pierce, A. et al. AXL and TYRO3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol. Endocrinol. 22, 2481–2495 (2008).
Salian-Mehta, S., Xu, M. & Wierman, M. E. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. Mol. Cell. Endocrinol. 374, 92–100 (2013).
Lee, H. J., Jeng, Y. M., Chen, Y. L., Chung, L. & Yuan, R. H. GAS6/AXL pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 35, 769–775 (2014).
Allen, M. P. et al. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving GAS6/ARK signaling to p38 mitogen-activated protein kinase. Mol. Cell. Biol. 22, 599–613 (2002).
Allen, M. P. et al. Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires RAC activation of the extracellular signal-regulated kinase pathway. J. Biol. Chem. 277, 38133–38140 (2002).
Kariolis, M. S. et al. An engineered AXL 'decoy receptor' effectively silences the GAS6–AXL signaling axis. Nature Chem. Biol. 10, 977–983 (2014).
Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 11, 889–896 (2010).
Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286–291 (2013).
Rothlin, C. V. & Lemke, G. TAM receptor signaling and autoimmune disease. Curr. Opin. Immunol. 22, 740–746 (2010).
Khan, T. N., Wong, E. B., Soni, C. & Rahman, Z. S. Prolonged apoptotic cell accumulation in germinal centers of MER-deficient mice causes elevated B cell and CD4+ TH cell responses leading to autoantibody production. J. Immunol. 190, 1433–1446 (2013).
Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014).
Ehrchen, J. et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109, 1265–1274 (2007).
DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Med. 19, 1264–1272 (2013).
Loges, S. et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen GAS6. Blood 115, 2264–2273 (2010).
Jacobsen, K. M. et al. Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013).
Stanford, J. C. et al. Efferocytosis produces a pro-metastatic landscape during post-partum mammary gland involution. J. Clin. Invest. http://dx.doi.org/10.1172/JCI76375 (2014).
Zhao, Y. et al. Differential expression of AXL and correlation with invasion and multidrug resistance in cancer cells. Cancer Invest. 30, 287–294 (2012).
Macleod, K. et al. Altered ERBB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65, 6789–6800 (2005).
Zhu, S. et al. A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc. Natl Acad. Sci. USA 106, 17025–17030 (2009).
Wang, Y. et al. MER receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32, 872–882 (2013).
Mahadevan, D. et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26, 3909–3919 (2007).
Dufies, M. et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874–885 (2011).
Gioia, R. et al. Quantitative phosphoproteomics revealed interplay between SYK and LYN in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118, 2211–2221 (2011).
Liu, L. et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871–6878 (2009).
Meyer, A. S., Miller, M. A., Gertler, F. B. & Lauffenburger, D. A. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6, ra66 (2013).
Ware, K. E. et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2–FGFR1 autocrine growth loop. Oncogenesis 2, e39 (2013). References 155 and 156 show that AXL is upregulated as a mechanism of acquired resistance to a variety of TKIs in breast and lung cancer cell lines.
Kim, H. R. et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4–ALK translocation. Mol. Oncol. 7, 1093–1102 (2013).
Huang, F. et al. Differential mechanisms of acquired resistance to insulin-like growth factor 1 receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 70, 7221–7231 (2010).
Brand, T. M. et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 74, 5152–5164 (2014).
Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genet. 44, 852–860 (2012). This paper shows that upregulation of GAS6–AXL autocrine signalling leads to EMT and that this is a mechanism to escape EGFR inhibition in NSCLC.
Khoury, H. J. et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119, 3403–3412 (2012).
Zhang, Y. X. et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68, 1905–1915 (2008).
Knubel, K. H. et al. MERTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget 5, 1338–1351 (2014).
Rettew, A. N. et al. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1, e34 (2012).
Liu, J. et al. Discovery of novel small molecule MER kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med. Chem. Lett. 3, 129–134 (2012).
Liu, J. et al. UNC1062, a new and potent MER inhibitor. Eur. J. Med. Chem. 65, 83–93 (2013).
Zhang, W. et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J. Med. Chem. 57, 7031–7041 (2014).
DeRyckere, D. et al. Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia. in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013).
Earp, H. S. et al. A small molecule MER tyrosine kinase inhibitor (UNC MERTKi) effectively inhibits growth of murine melanoma. in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013).
Powell, N. A. et al. Novel and selective spiroindoline-based inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 22, 190–193 (2012).
Powell, N. A. et al. Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 23, 1051–1055 (2013).
Powell, N. A. et al. Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 23, 1046–1050 (2013).
Cummings, C. T. et al. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 26 June 2014.
Demarest, S. J. et al. Evaluation of TYRO3 expression, GAS6-mediated AKT phosphorylation, and the impact of anti-TYRO3 antibodies in melanoma cell lines. Biochemistry 52, 3102–3118 (2013).
Cerchia, L. et al. Targeting AXL with an high-affinity inhibitory aptamer. Mol. Ther. 20, 2291–2303 (2012).
Avilla, E. et al. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 71, 1792–1804 (2011).
Sather, S. et al. A soluble form of the MER receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109, 1026–1033 (2007).
Morizono, K. et al. The soluble serum protein GAS6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase AXL to mediate viral entry. Cell Host Microbe 9, 286–298 (2011).
Shimojima, M. et al. TYRO3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109–10116 (2006).
Morizono, K. & Chen, I. S. The role of phosphatidylserine receptors in enveloped virus infection. J. Virol. 88, 4275–4290 (2014).
Meertens, L. et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12, 544–557 (2012).
Rahman, Z. S., Shao, W. H., Khan, T. N., Zhen, Y. & Cohen, P. L. Impaired apoptotic cell clearance in the germinal center by MER-deficient tingible body macrophages leads to enhanced antibody-forming cell and germinal center responses. J. Immunol. 185, 5859–5868 (2010).
Williams, J. C., Wagner, N. J., Earp, H. S., Vilen, B. J. & Matsushima, G. K. Increased hematopoietic cells in the Mertk−/− mouse peritoneal cavity: a result of augmented migration. J. Immunol. 184, 6637–6648 (2010).
Weinger, J. G. et al. Loss of the receptor tyrosine kinase AXL leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J. Neuroinflamm. 8, 49 (2011).
Subramanian, M. et al. An AXL/LRP1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J. Clin. Invest. 124, 1296–1308 (2014).
Bosurgi, L. et al. Paradoxical role of the proto-oncogene AXL and MER receptor tyrosine kinases in colon cancer. Proc. Natl Acad. Sci. USA 110, 13091–13096 (2013).
Tang, H. et al. TAM receptors and the regulation of erythropoiesis in mice. Haematologica 94, 326–334 (2009).
Lu, Q. et al. TYRO3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723–728 (1999). In this study, deletion of all three TAM RTKs is shown to result in a dramatic hyperinflammatory phenotype that is characterized by severe lymphoproliferation and results in broad spectrum autoimmunity.
Li, Q., Lu, Q., Lu, H., Tian, S. & Lu, Q. Systemic autoimmunity in TAM triple knockout mice causes inflammatory brain damage and cell death. PLoS ONE 8, e64812 (2013).
Qi, N. et al. Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking TYRO3, AXL and MER receptor tyrosine kinases. PLoS ONE 8, e66604 (2013).
Caraux, A. et al. Natural killer cell differentiation driven by TYRO3 receptor tyrosine kinases. Nature Immunol. 7, 747–754 (2006).
Wang, H. et al. The role of TYRO 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica 92, 643–650 (2007).
Binder, M. D. et al. GAS6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. J. Neurosci. 28, 5195–5206 (2008).
Binder, M. D. et al. GAS6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination. PLoS ONE 6, e17727 (2011).
Fourcot, A. et al. GAS6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. Am. J. Physiol-Gaster. L. 300, G1043–G1053 (2011).
Hagstrom, S. A., Duyao, M., North, M. A. & Li, T. Retinal degeneration in Tulp1−/− mice: vesicular accumulation in the interphotoreceptor matrix. Invest. Ophthalmol. Vis. Sci. 40, 2795–2802 (1999).
Stubdal, H. et al. Targeted deletion of the tub mouse obesity gene reveals that tubby is a loss-of-function mutation. Mol. Cell. Biol. 20, 878–882 (2000).
Sano, H. et al. Critical role of galectin-3 in phagocytosis by macrophages. J. Clin. Invest. 112, 389–397 (2003).
Abdel-Aziz, H. O. et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J. Cancer Res. Clin. Oncol. 134, 777–788 (2008).
The authors thank A. Holtzhausen for her contribution to figure 2 and for her critical reading of the manuscript; S. Sather for her analysis of mutations in TAM family kinases; and S. Frye for helpful conversations. This work was supported by grants from the US National Cancer Institute (NCI) (to D.K.G. and H.S.E.), from the UNC Breast Cancer SPORE (to H.S.E.) and from the Breast Cancer Research Foundation (to H.S.E.).
D.K.G. and H.S.E. are co-founders of Meryx, Inc., a company developing small-molecule MERTK kinase inhibitors. D.D. holds stock in Meryx, Inc.
Supplementary information S1 (table) | Expression and function of TAM-family kinases and ligands in specific tumor types* (PDF 277 kb)
- M2-polarized macrophage
An alternatively activated macrophage that secretes immunosuppressive cytokines and growth factors to promote tissue repair.
The process by which macrophages and epithelial cells ingest apoptotic material.
- Retinitis pigmentosa
An inflammatory process that occurs in the lining of the retina of the eye.
The process that occurs after lactation ceases, which results in substantial cell death in the milk-producing epithelium of the mammary gland.
Epithelial cells that wrap around the capillaries in the glomeruli of the kidney.
- Sertoli cells
The cells in the male gonad that nourish the sperm-producing processes.
- M1 macrophage
A macrophage that is activated by cytokines, or that is in contact with or has ingested foreign material, resulting in release of cytokines that initiate or prolong an inflammatory innate immune response.
(LPS). A bacterial product that is sensed by specific Toll-like receptors on innate immune cells, which triggers a robust inflammatory response.
Animals that have a notochord, a dorsal nerve chord and gill slits at one or more stages of development. This includes the vertebrates.
- Non-oncogene addiction
Increased dependence of the neoplastic cell on the induction of endogenous cellular survival factors needed to prevent apoptosis in response to the hyperproliferative and altered metabolic states driven by oncogene expression or tumour suppressor loss.
- Tingible body macrophages
Macrophages in the lymph node germinal centres that help to maintain tolerance to 'self' antigens.
- Postpartum breast cancer
Breast cancer diagnosed in women after delivery of offspring. For reasons that have not been elucidated, the prognosis of postpartum breast cancer is worse than that of breast cancer diagnosed during pregnancy, even though both groups of women are premenopausal.
A synthesized RNA that is made or selected to bind to a specific target (usually a protein) with high affinity to modulate its function.
About this article
Cite this article
Graham, D., DeRyckere, D., Davies, K. et al. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14, 769–785 (2014). https://doi.org/10.1038/nrc3847
Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy
Cancer Letters (2021)
Design and Synthesis of 5‐Aryl ‐substituted Phenylpyrimidine‐2,4‐diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors
Bulletin of the Korean Chemical Society (2021)
Expert Opinion on Therapeutic Targets (2021)
Frontiers in Cellular and Infection Microbiology (2021)
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer